Compare Alcon AG (ALC) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs T Rowe Price Group Inc — how do they compare? Alcon AG trades at $66.97 (market cap $32.69B), while T Rowe Price Group Inc trades at $117.09 (market cap $25.75B). The key difference: Alcon AG is the larger of the two by market cap, and T Rowe Price Group Inc pays the higher dividend (4.33%). Which is the better fit depends on your goals.
| ALC | TROW | |
|---|---|---|
Market Cap | $32.69B | $25.75B |
Sector | Health | Financials |
52-Week High | $92.22 | $120.16 |
52-Week Low | $62.02 | $86.19 |
Enterprise Value | $36.28B | $22.45B |
Dividend Yield | 0.54% | 4.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
T. Rowe Price (TROW) trades at $120.16, up 1.36% with bullish technical indicators showing strong momentum above key support levels. The company maintains solid fundamentals with $7.31B revenue, 28.28% net margin, and attractive valuation at 12.78 P/E. Recent earnings beat expectations in Q1 2026, while strategic initiatives in institutional services and AI-focused content demonstrate proactive positioning.
TROW presents a mixed outlook with strong profitability and cash flow generation offset by analyst caution. The stock trades above consensus target ($101.57) but offers dividend appeal with recent $1.30 payout. Key risks include equity outflows and market sensitivity, while institutional enhancements and debt-free balance sheet provide stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
